0
Deep & Emerging Tech·October 7, 2026·1 min read

Rivercell raises $25M to build an AI model of how cells respond to drugs

Share

$25M at seed for an AI “virtual cell” is a bet that in silico biology will move from screening aid to core decision engine in drug design. Pharma and biotech operators should start mapping where such models could collapse wet-lab cycles — and what data access or validation partnerships they’d need to plug into this stack.